High-yield continuous lentiviral vector bioprocessing through perfusion intensification and integrated cold chain affinity capture

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

High-yield continuous lentiviral vector bioprocessing through perfusion intensification and integrated cold chain affinity capture

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Perfusion intensification, cold harvest stabilization, and inline affinity capture together can more than double lentiviral vector (LVV) recovery while removing steps from the process. This session presents a continuous LVV workflow that reached around 12 × 10⁶ viable cells/mL before transfection and delivered roughly 16-fold higher cumulative transduction units over 3 days through cold harvest handling.

Keen Chung, Technical Lead for Viral Vector Culture and Analytics, will show how coupling affinity capture directly to the perfusion permeate eliminates clarification and bulk harvest storage, cutting hold times, contamination risk, and product loss.

Attend this webinar to:

Apply a perfusion intensification approach that reached around 12 × 10⁶ viable cells/mL before transfection, roughly 4-fold higher cell density, to raise vector yield and cell-specific productivity
Quantify how continuous cold harvest at 4°C delivered around 16-fold higher cumulative transduction units over 3 days, informed by an LVV infectivity half-life of around 6 h at 37°C versus around 300h at 4°C
See how affinity capture coupled directly to the permeate enables continuous, hold-free purification and removes clarification and bulk storage as separate unit operations
Compare overall recovery against a conventional depth filtration and anion exchange chromatography route (around 25%), which the integrated process improved more than 2.5-fold

Keen Chung, PhD

Technical Lead, Viral Vector Culture and Analytics at Repligen

Keen Chung, PhD, is technical lead for Viral Vector Culture and Analytics within the R&D at Repligen. He has over ten years of industry experience in viral vector upstream process development and bioanalytical characterization for gene therapy manufacturing. Keen holds a PhD in Molecular Toxicology from the Penn State University College of Medicine and completed postdoctoral training at UT Southwestern Medical Center and SRI International.

Prior to Repligen, he held scientific leadership roles at Pall Life Sciences, where he led analytical and upstream process development efforts supporting the optimization and scale-up of multiple viral vector manufacturing platforms. In his current role, Keen leads the development of advanced bioprocess technologies, with a focus on TFDF-based perfusion systems and viral vector analytics for cell and gene therapy applications.

In 40 Days

You have registered for this webinar